Quarterly report pursuant to Section 13 or 15(d)

Nature of Business and Liquidity (Details)

v3.20.2
Nature of Business and Liquidity (Details)
6 Months Ended
May 20, 2020
Nov. 01, 2018
Oct. 19, 2015
Jun. 30, 2020
clinicalTrial
candidate
approach
technology
Product Information [Line Items]        
Number of core drug technologies | technology       3
Number of drug candidates | candidate       5
Number of different approaches to treating cancer | approach       3
Number of clinical trials for drug candidates | clinicalTrial       2
Intertech Bio Corporation And The Board of Regents (Board) Of The University Of Texas System        
Product Information [Line Items]        
Investigational new drug application filed with Federal Drug Administration, period 9 months 18 months 3 years  
Commencement of Phase I study for licensed product, period 2 years 6 months 3 years 6 months 5 years  
Potential extension period 18 months      
Food and Drug Administration        
Product Information [Line Items]        
Market exclusivity extension period       5 years
European Union        
Product Information [Line Items]        
Market exclusivity extension period       10 years
Licensing Agreements        
Product Information [Line Items]        
Market exclusivity period       7 years
Animal Life Science        
Product Information [Line Items]        
Ownership interest       10.00%